Journal of Hematology & Oncology (Dec 2021)

WDR26 and MTF2 are therapeutic targets in multiple myeloma

  • Fumou Sun,
  • Yan Cheng,
  • Jesse D. Riordan,
  • Adam Dupuy,
  • Wendy Dubois,
  • Michael Pisano,
  • Jing Dong,
  • Beverly Mock,
  • Fenghuang Zhan,
  • Parameswaran Hari,
  • Siegfried Janz

Journal volume & issue
Vol. 14, no. 1
pp. 1 – 7


Read online

Abstract Unbiased genetic forward screening using retroviral insertional mutagenesis in a genetically engineered mouse model of human multiple myeloma may further our understanding of the genetic pathways that govern neoplastic plasma cell development. To evaluate this hypothesis, we performed a tumor induction study in MYC-transgenic mice infected as neonates with the Moloney-derived murine leukemia virus, MOL4070LTR. Next-generation DNA sequencing of proviral genomic integration sites yielded rank-ordered candidate tumor progression genes that accelerated plasma cell neoplasia in mice. Rigorous clinical and biological validation of these genes led to the discovery of two novel myeloma genes: WDR26 (WD repeat-containing protein 26) and MTF2 (metal response element binding transcription factor 2). WDR26, a core component of the carboxy-terminal to LisH (CTLH) complex, is overexpressed or mutated in solid cancers. MTF2, an ancillary subunit of the polycomb repressive complex 2 (PRC2), is a close functional relative of PHD finger protein 19 (PHF19) which is currently emerging as an important driver of myeloma. These findings underline the utility of genetic forward screens in mice for uncovering novel blood cancer genes and suggest that WDR26-CTLH and MTF2-PRC2 are promising molecular targets for new approaches to myeloma treatment and prevention.